Drug Type Fusion protein |
Synonyms |
Target |
Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), SIRPα inhibitors(Signal-regulatory protein alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 2 | CN | 31 Aug 2021 | |
Neoplasms | Phase 2 | CN | 31 Aug 2021 | |
Non-Hodgkin Lymphoma | Phase 1 | CN | 30 Jan 2022 | |
Non-Hodgkin Lymphoma | Phase 1 | US | 30 Jan 2022 | |
Solid tumor | Phase 1 | US | 30 Jan 2022 | |
Solid tumor | Phase 1 | CN | 30 Jan 2022 |